DOI: 10.12890/2024_004981

Can you diagnose immune thrombocytopenia in myeloma? A case of thrombocytopenia in a patient with multiple myeloma

Authors

  • Cláudia Diogo Department of Internal Medicine, Unidade Local de Saúde da Região de Leiria, Leiria, Portugal
  • Carolina Fernandes Department of Internal Medicine, Unidade Local de Saúde da Região de Leiria, Leiria, Portugal
  • Sandra Cunha Department of Internal Medicine, Unidade Local de Saúde da Região de Leiria, Leiria, Portugal
  • Luís Luz Department of Internal Medicine, Unidade Local de Saúde da Região de Leiria, Leiria, Portugal
  • João Gaião Santos Blood Department, Unidade Local de Saúde da Região de Leiria, Leiria, Portugal
  • Joana Raquel Monteiro Department of Internal Medicine, Unidade Local de Saúde da Região de Leiria, Leiria, Portugal

claudia.o.diogo@gmail.com

Keywords

Multiple myeloma, immune thrombocytopenia, differential diagnosis, association, chemotherapy

Abstract

Multiple myeloma (MM) is the second most common haematological malignancy, the diagnosis of which has doubled in recent years. Immune thrombocytopenia consists of isolated thrombocytopenia secondary to antibody mediated peripheral platelet destruction. In most cases, there is no identifiable cause (primary immune thrombocytopenia). Its association with multiple myeloma is rare. Early recognition of this association is essential for raising awareness among clinicians, allowing for a rapid differential diagnosis and therapeutic optimization, reducing side effects and improving prognosis. Thus, we present a clinical case of concomitant immune thrombocytopenia and MM, whose initial presentation was thrombocytopenia. This clinical case is the first case among thirteen described in the literature in which chemotherapy was the initial treatment for both pathologies, as seen in this review.

View the entire article

Downloads

References

  1. Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. ESMO Guidelines Committee. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021;32:309-322.
  2. Usmani SZ, Hoering A, Cavo M, Miguel JS, Goldschimdt H, Hajek R, Turesson I, et al. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project. Blood Cancer J 2018;8:123.
  3. Sarfraz H, Anand K, Liu S, Shah S. Multiple myeloma with concurrent immune thrombocytopenic purpura. Ecancer medical science 2020;14:1012.
  4. Jain A, Khunger JM, Kapahtia S, Prasad P, Gupta DK, Chaudhry S. Smoldering Multiple Myeloma Presenting as Immune Thrombocytopenia. Indian J Hematol Blood Transfus 2019;35:565-566.
  5. Verdirame JD, Feagler JR, Commers JR. Multiple myeloma associated with immune thrombocytopenic purpura. Cancer 1985;56:1199-1200.
  6. Richardson PG, Oriol A, Larocca A, Bladé J, Cavo M, Rodriguez-Otero P, et al. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. J ClinOncol 2021;39:757-767.
  7. Gupta V, Hegde UM, Parameswaran R, Newland AC. Multiple myeloma and immune thrombocytopenia. Clin Lab Haematol 2000;22:239-242.
  8. Falco P, Bertola A, Bringhen S, Cavallo F, Boccadoro M, Palumbo A. Successful management of immune thrombocytopenic purpura with thalidomide in a patient with multiple myeloma. Hematol J 2004;5:456-457.
  9. Yao H, Zhang X, Liu J, Zhu L, Chen G, Wu S, et al. Multiple myeloma developing during long-term clinical course of refractory immune thrombocytopenic purpura: a case report and review of literature. Int J Clin Exp Pathol 2015;8:15429-15432.
  10. Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 2022;97:1086-1107.
  11. Shimanovsky A, Alvarez Argote J, Murali S, Dasanu CA. Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance. BBA Clin 2016;6:12-18.
  12. Faller E, Chapman L, Enright H, Browne P, McHugh J, Desmond R. Immune thrombocytopenia purpura associated with multiple myeloma. AnnHematol 2016;95:1371-1372.
  13. Siniscalchi A, Stasi R, Fratoni S, de Fabritiis P, Caravita T. Management of immune thrombocytopoenia in a patient with newly-diagnosed smouldering myeloma and colorectal cancer. BMJ Case Rep 2009;2009:bcr03.2009.1715.
  14. Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 2019;3:3780-3817.
  15. Ejaz A, Radia D. Diagnosis and management of primary immune thrombocytopenia in adults. Br J Hosp Med (Lond) 2019;80:C54-C57.
  16. Althaus K, Faul C, Bakchoul T. New Developments in the Pathophysiology and Management of Primary Immune Thrombocytopenia. Hamostaseologie 2021;41:275-282.
  17. Tabata R, Tabata C, Tazoh A, Nagai T. Low dose cepharanthine ameliorates immune thrombocytopenic purpura associated with multiple myeloma. IntImmunopharmacol 2012;13:242-244.

Published

2024-11-11

Issue

Vol. 11 No. 12 (2024)

Categories

How to Cite

1.
Diogo C, Fernandes C, Cunha S, Luz L, Santos JG, Monteiro JR. Can you diagnose immune thrombocytopenia in myeloma? A case of thrombocytopenia in a patient with multiple myeloma. EJCRIM [Internet]. 2024 Nov. 11 [cited 2026 Nov. 3];11(12). Available from: https://ejcrim.com/index.php/ejcrim/article/view/4981

Most read articles by the same author(s)